# Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

> **NCT03238248** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 71 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Azacitidine Subcutaneous Injection or Intravenous Infusion
- **DRUG:** Pevonedistat Infusion
- **PROCEDURE:** Bone Marrow Biopsy & Aspirate

## Key facts

- **NCT ID:** NCT03238248
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-07
- **Primary completion:** 2022-09-30
- **Final completion:** 2023-11-27
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2024-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238248, "Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03238248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*